Immorna Biotherapeutics granted FDA IND clearance for Phase I/II JCXH-211 study
The tumour-eradicating potential of Immorna Biotherapeutics's JCXH-211 IV has already been demonstrated in mice.
Immuno
Anti-obesity drugs will be 2024’s defining trend
ASCO24: AbbVie flexes early success of ADC pipeline in solid tumours
ASCO24: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
ASCO24: MSD’s ADC shows efficacy in lung and breast tumours
MRD endpoint expected to usher new era for MM therapies
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
SecondWave’s ultrasound therapy improves rheumatoid arthritis in pilot study
